GLOW Stack
GHK-Cu + BPC-157 + TB-500 skin-and-healing blend
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The combination has never been tested in people. There is no trial, no case series, and no published pharmacokinetic work on the three peptides given together, so any claim about the blend outperforming its parts is marketing rather than evidence. Component by component the picture is thin. GHK-Cu has small human studies as a topical cosmetic ingredient, often industry linked and short, showing modest changes in skin appearance; injected GHK-Cu in humans is essentially unstudied. BPC-157 rests almost entirely on rodent work from a small number of laboratories, with tendon, gut and vascular findings that have not been replicated by independent human trials. TB-500 has no controlled human data under that name, and the parent molecule thymosin beta-4 was studied in humans mainly as an eye drop and topical preparation, not as a subcutaneous fragment. Additive benefit is assumed, never demonstrated, and interaction between a copper-carrying peptide and two angiogenic repair peptides has not been examined at all. Treat the whole entry as unstudied territory dressed in the vocabulary of published science.
- FDA
- None of the three ingredients is an FDA-approved drug. In late 2023 the FDA put BPC-157 and TB-500 on a restricted list (Category 2) that blocks pharmacies from compounding them. Most product sold is labeled research-use-only, not for human use.
- WADA
- Prohibited
Reference only. Not medical advice.
What can go wrong
Honest risk is high. None of the three peptides is an FDA-approved drug, and two of them (BPC-157, TB-500) were placed in a restricted FDA category over safety and impurity concerns. The blend has zero published human trials, so safety and dosing in people are unknown. Product is overwhelmingly sold as research-use-only, meaning purity, sterility, and actual contents are unregulated and vary by vendor. Injection itself carries risks of infection, bruising, and reactions to contaminants. Long-term effects are unstudied, and the copper component (GHK-Cu) raises a theoretical concern about copper buildup with heavy use.
Talk to a clinician before taking this. The Atlas can tell you what has been studied about GLOW Stack. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
GLOW is an informal blend of three peptides sold together for skin quality, wound healing, and a cosmetic glow. A peptide is a short chain of amino acids, the building blocks that make up proteins. The three parts are GHK-Cu (a copper-carrying tripeptide linked to collagen, the protein that gives skin its structure), BPC-157 (a synthetic peptide studied for tissue repair), and TB-500 (a fragment of a natural healing protein). It is usually injected under the skin, though it is legally sold as a research chemical rather than a medicine. No clinical trial has ever tested this specific three-peptide combination in people. The name and recipe come from the online peptide and biohacker community, not from any medical body.
Cosmetic and healing blend
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Safety in detail
Nothing in this blend is an approved medicine anywhere. Two components sit in the FDA's Category 2 bulk substances list, which effectively closed the US compounding pharmacy route and pushed supply toward research-chemical vendors. For athletes, TB-500 falls under the WADA prohibition on growth factors and peptide hormones, and BPC-157 is likewise prohibited; GHK-Cu is not itself banned, which does not help if it arrives in the same syringe. Grey market vials carry real risk of underdosing, wrong contents, endotoxin, and non-sterile reconstitution. The combination specifically has no human safety data, no dosing precedent, and no information on whether copper loading alongside repair peptides matters over months of use.
What people get wrong
Often saidMyth: GLOW is a regulated branded medicine.
ActuallyReality: GLOW is a marketing name used by sellers, not an FDA-approved product.
Often saidMyth: A blend sold by a clinic must be tested.
ActuallyReality: This specific three-peptide combination has no published human trials; two components are FDA-restricted.
Who profits, and who pushes back
US Food and Drug Administration
Placed BPC-157 and TB-500 in a restricted category, citing safety, impurity, and insufficient human-data concerns.
Banned Substances Control Group (BSCG)
Flags TB-500 as banned in sport with an unestablished human safety profile.
Independent pharmacologists
Note that most BPC-157 evidence traces to a single research group and that combination claims are extrapolated from animal data, not human trials.
Compounding pharmacies and peptide vendors
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Market the blend as a single product; direct financial interest in sales.
Telehealth peptide clinics
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Offer GLOW as a recurring program; revenue tied to subscriptions.
Aesthetic and wellness influencers
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Some disclose affiliate or sponsor ties; others appear to be unpaid believers reporting personal results.
Jay Campbell and similar peptide-community figures
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Publish detailed protocols; often monetize via products, courses, or affiliate links. Belief and commerce overlap.
Where the research comes from
Most of the published research on this comes from one place. 60% of it is from United States. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| United States | 60% |
| Europe | 18% |
| Other | 12% |
| Australia and New Zealand | 10% |
Research published from: US.
How we got here
GLOW has no documented inventor. The label surfaced in vendor catalogues and forum threads in the late 2010s and spread through Reddit, Discord servers, and cosmetic wellness clinics that already offered injectables. Sellers vary the ratio freely and some keep the name while swapping or adding a component, so two vials labelled GLOW are not reliably the same product. The parts have unrelated origins. GHK-Cu was identified by Loren Pickart during work on human plasma in San Francisco and reported in Nature New Biology in 1973. It later became an ordinary cosmetic ingredient in topical serums sold in Europe, Asia and North America, which lends the blend a veneer of familiarity it has not earned in injected form. BPC-157 came from Predrag Sikiric and colleagues in Zagreb, who described it as a gastric pentadecapeptide with protective effects across many rodent tissues. TB-500 is a seller's name for a synthetic acetylated fragment of thymosin beta-4, a molecule that did reach human trials as RGN-259 for eye and wound indications before those programmes lost momentum. The stack itself is a commercial assembly, put together by the market rather than by any lab.
The name GLOW is community-attributed within the online peptide and biohacker scene; no documented individual or company is credited with coining it, and the origin is uncertain. The recipe combines three separately developed peptides. GHK-Cu was isolated from human blood plasma by biochemist Loren Pickart, described in Nature New Biology in 1973. BPC-157 was developed and studied by Predrag Sikiric and colleagues at the University of Zagreb in Croatia, derived from a protein found in gastric (stomach) juice. TB-500 is a synthetic version of a segment of thymosin beta-4, a natural healing protein first identified in thymus tissue. The three were bundled and branded GLOW by vendors and community members, not by any of the original researchers, and the blend has not been independently validated as a protocol.
- 1973GHK-Cu isolated from human plasma by Loren Pickart
- 1990s-2000sBPC-157 studied by Sikiric group in Zagreb; thymosin beta-4 research expands
- 2010sPeptides spread through bodybuilding and biohacker communities as research chemicals
- Early 2020sGLOW blend branded and sold by vendors and telehealth clinics
- 2022WADA lists BPC-157 and TB-500 as banned substances
- Late 2023FDA places BPC-157 and TB-500 in restricted compounding category
At a glance
- Components
- GHK-Cu, BPC-157, TB-500
- Human trials of the blend
- None published
- Typical sold ratio
- About 5:1:1 GHK-Cu heavy
- Regulatory status
- Not FDA-approved; mostly research-use-only
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about GLOW Stack. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
BPC-157 and TB-500 were placed in the FDA's Category 2 bulk drug substances list, blocking compounding on safety and characterisation grounds.
Peptide growth factors including thymosin beta-4 derivatives such as TB-500 are prohibited at all times for athletes, and BPC-157 is likewise prohibited.
Anti-doping education bodies have warned athletes that BPC-157 and TB-500 are banned and are sold only as unapproved research chemicals.
U.S. Anti-Doping Agency
GHK was first isolated and described from human plasma by Loren Pickart, establishing the copper tripeptide later used in cosmetics.
Nature New Biology (Pickart and Thaler, 1973)
The BPC-157 literature is dominated by rodent studies from a single Zagreb research group, with no completed independent human efficacy trials published.
University of Zagreb School of Medicine (Sikiric and colleagues, collected reviews)
Thymosin beta-4 was developed for human use as RGN-259 in ophthalmic and wound indications, which is distinct from the injected TB-500 fragment sold online.
Topical copper tripeptide preparations have only small, often industry-affiliated human cosmetic studies, with no injected human data.
No registered or published clinical trial exists for the GHK-Cu, BPC-157 and TB-500 combination in humans.